First Patient Dosed in FORTIS Trial of AT845 for LOPD
The first patient has been dosed in the FORTISÂ Phase 1/2 trial of AT845, a single-dose gene therapy for adults with late-onset Pompe disease (LOPD). AT845 is designed to deliver a healthy copy of the gene that encodes the enzyme acid alpha-glucosidase (GAA) directly to…